Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
MDVN [NASD]
Medivation, Inc.
Index- P/E349.64 EPS (ttm)0.28 Insider Own0.20% Shs Outstand76.79M Perf Week9.23%
Market Cap7.52B Forward P/E28.37 EPS next Y3.45 Insider Trans11.63% Shs Float75.47M Perf Month-0.70%
Income23.70M PEG- EPS next Q0.82 Inst Own96.70% Short Float4.46% Perf Quarter29.74%
Sales391.90M P/S19.18 EPS this Y-1.80% Inst Trans0.75% Short Ratio2.95 Perf Half Y69.61%
Book/sh1.87 P/B52.35 EPS next Y41.84% ROA5.80% Target Price107.39 Perf Year81.67%
Cash/sh3.78 P/C25.92 EPS next 5Y- ROE26.20% 52W Range48.15 - 103.88 Perf YTD53.40%
Dividend- P/FCF256.58 EPS past 5Y11.70% ROI-7.90% 52W High-5.76% Beta0.77
Dividend %- Quick Ratio4.80 Sales past 5Y85.00% Gross Margin- 52W Low103.32% ATR3.82
Employees433 Current Ratio4.80 Sales Q/Q111.30% Oper. Margin11.90% RSI (14)56.63 Volatility4.40% 3.93%
OptionableYes Debt/Eq1.50 EPS Q/Q957.10% Profit Margin6.00% Rel Volume0.61 Prev Close96.97
ShortableYes LT Debt/Eq1.50 EarningsNov 10 AMC Payout0.00% Avg Volume1.16M Price97.90
Recom1.80 SMA201.71% SMA504.65% SMA20026.69% Volume710,474 Change0.96%
18-Sep-14Upgrade Canaccord Genuity Hold → Buy $60 → $132
12-Sep-14Reiterated Chardan Capital Markets Buy $100 → $122
11-Sep-14Reiterated Stifel Buy $89 → $112
08-Aug-14Reiterated UBS Buy $85 → $90
08-Aug-14Reiterated Stifel Buy $83 → $89
08-Aug-14Reiterated Brean Capital Buy $100 → $105
22-May-14Initiated Stifel Buy $81
16-Apr-14Initiated Canaccord Genuity Hold $60
17-Mar-14Reiterated Maxim Group Buy $92 → $112
03-Mar-14Reiterated UBS Buy $93 → $85
28-Feb-14Reiterated Maxim Group Buy $84 → $92
03-Feb-14Reiterated Chardan Capital Markets Buy $100
03-Feb-14Downgrade Needham Buy → Hold
29-Jan-14Reiterated Maxim Group Buy $75 → $84
29-Jan-14Reiterated Brean Capital Buy $72 → $100
29-Jan-14Reiterated Aegis Capital Buy $100 → $125
28-Jan-14Initiated CRT Capital Buy $88
10-Jan-14Reiterated Barclays Equal Weight $57 → $62
13-Nov-13Reiterated Maxim Group Buy $71 → $75
13-Nov-13Reiterated Barclays Equal Weight $53 → $57
22-Oct-14 07:32AM  Orexigen (OREX) Shows Strength: Stock Gains 11.1% Zacks
06:43AM  Illumina (ILMN) Looks Strong: Stock Gains 9.2% Zacks
21-Oct-14 05:05PM  NewLink-Roche Ink Deal for Oncology Candidate Development Zacks
02:30PM  Will Quest Diagnostics (DGX) Surprise Earnings in Q3? Zacks
17-Oct-14 05:07PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
04:00PM  Infinity Pharmaceuticals' Duvelisib Fails in Mid-Stage Study Zacks
03:30PM  Gilead's Harvoni Receives Notice of Compliance from Canada Zacks
15-Oct-14 05:48PM  GW Pharmaceuticals Down on Disappointing Mid-Stage Data Zacks
04:20PM  Novavax Begins Mid-Stage Study on RSV Vaccine in Elders Zacks
03:30PM  Alnylam Reveals Positive Data from its Pipeline Candidates Zacks
14-Oct-14 11:54AM  J&J Earnings Beat; Olysio Chatter Hits Gilead at Investor's Business Daily
13-Oct-14 04:50PM  Isis Pharmaceuticals Unveils Mid-Stage Data on ISIS-SMNRx Zacks
04:19PM  Celgene's Otezla Encourages in Plaque Psoriasis at EADV Zacks
03:00PM  Targacept's Nine-Year Association with AstraZeneca to End Zacks
10-Oct-14 04:52PM  AstraZeneca's Benralizumab Encourages in Phase II Study Zacks
04:10PM  XOMA Starts Phase I Study on XOMA 358 for Hyperinsulinism Zacks
03:45PM  Momenta Reveals Necuparanib Data for Pancreatic Cancer Zacks
09-Oct-14 05:44PM  What's the Dollar Value of Online Patient Chatter? at BusinessWeek
03:44PM  Amgen Up on Positive Phase III Data on Psoriasis Biosimilar Zacks
03:30PM  Chimerix Falls as Ebola Patient on Brincidofovir Dies in US Zacks
02:26PM  EY Announces leaders from Medivation, MongoDB, Trulia, and zulily inc. recipients of its 2014 Venture Capital Award of Excellence PR Newswire
08-Oct-14 04:50PM  Emergent BioSolutions Revamps Business to Drive Earnings Zacks
10:20AM  Amgen's Data on Evolocumab Published in The Lancet Zacks
06-Oct-14 01:31PM  Consider Medivation for Your Portfolio at Fox Business
04-Oct-14 12:01AM  [$$] A Poor Quarter for U.S. Equity Funds at Barrons.com
03-Oct-14 04:10PM  MannKind Receives $150 Million Upfront Payment from Sanofi Zacks
02-Oct-14 09:20AM  5 Big-Volume Stocks to Trade for Big Breakouts at TheStreet
12:01AM  Hedge Funds Listen In on Patient Chats for Pharma Bets Bloomberg
29-Sep-14 04:30PM  Agios to Present Data on AG-120 in November, Shares Rises Zacks
26-Sep-14 04:10PM  Alnylam Starts New Study on Cardiac Amyloidosis Patients Zacks
24-Sep-14 05:10PM  Novavax's Influenza Vaccine Study Shows Adjuvant Efficiency Zacks
05:00PM  Gilead (GILD) Seeks Japanese Approval for HCV Combo Drug Zacks
11:42AM  How Will Medivation (MDVN) Stock Be Affected Today by This Analyst Action? at TheStreet
11:42AM  [video]How Will Medivation (MDVN) Stock Be Affected Today by This Analyst Action? at TheStreet
22-Sep-14 07:00PM  Cramer's favorite IPO of 2014: Not Alibaba CNBC
07:00PM  [video] Cramer's favorite IPO of 2014: Not Alibaba at CNBC
05:11PM  Today's Market Thorns, Roses and All Time Highs... Yahoo Finance Blogs
04:20PM  Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer Zacks
18-Sep-14 01:55PM  Canaccord Genuity Doubles Price Target for Medivation 24/7 Wall St.
08:53AM  Medivation upgraded by Canaccord Genuity Briefing.com
08:23AM  Analysts' Actions: Kohl's, Medivation, Owens-Illinois, Pier 1, More TheStreet
15-Sep-14 07:05AM  Quarterly Changes to the NASDAQ Q-50 Index GlobeNewswire
12-Sep-14 05:24PM  Your first trade for Monday at CNBC
12:58PM  [video] FMHR Final Trade: MDVN, C, NUE at CNBC
11-Sep-14 05:41PM  Medivation Eyes Blockbuster As Cancer Drug Gets An OK at Investor's Business Daily
05:35PM  Medivation-Astellas' Xtandi's Label Expanded by FDA Zacks
08:32AM  Stifel Raises Medivation Inc Price Target Benzinga
10-Sep-14 06:40PM  U.S. FDA approves expanded use of Medivation prostate cancer drug Reuters
05:21PM  U.S. FDA okays expanded use of Medivation prostate cancer drug Reuters
05:08PM  Medivation Resumes Trading After Xtandi Receives FDA Approval at Barrons.com
04:39PM  U.S. FDA Approves New Indication for the Use of XTANDI┬« (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer PR Newswire
04:20PM  U.S. FDA Approves New Indication for the Use of XTANDI(R) (Enzalutamide) Capsules for Patients With Metastatic Castration-Resistant Prostate Cancer Marketwired
03:37PM  Medivation Prostate Cancer Drug Secures Expanded FDA Label at TheStreet
05-Sep-14 08:55AM  Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte at TheStreet
03-Sep-14 11:50AM  Credit Suisse Positive on Some Biotechs, Very Cautious on Others at 24/7 Wall St.
25-Aug-14 04:10PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired +5.04%
06:48AM  Can Medivation (MDVN) Run Higher on Strong Earnings Estimate Revisions? Zacks
19-Aug-14 04:25PM  Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 Zacks
15-Aug-14 01:04PM  MEDIVATION, INC. Financials EDGAR Online Financials
11-Aug-14 11:10AM  Medivation Jumps on Q2 Earnings Beat, Outlook Encourages Zacks
06:36AM  Medivation (MDVN) Jumps: Stock Adds 7.5% in Session Zacks
08-Aug-14 12:03PM  Midday movers: Allergan, McDonald's, Sotheby's & More at CNBC +7.52%
12:03PM  Why Medivation (MDVN) Stock Is Gaining Today at TheStreet
11:55AM  Medivation Cancer Drug Fuels Beat, Swings To Profit at Investor's Business Daily
07-Aug-14 04:23PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:10PM  Medivation Reports Second Quarter Financial Results and Provides Corporate Update Marketwired
07:07AM  Q2 2014 Medivation, Inc. Earnings Release - After Market Close CCBN
29-Jul-14 06:54AM  [$$] Undervalued Biotech Stocks Beat the Index at Barrons.com
24-Jul-14 04:10PM  Medivation Announces Second Quarter 2014 Financial Results Teleconference on August 7, 2014 Marketwired
12:34PM  [video] Who's afraid of Janet Yellen? at CNBC
21-Jul-14 03:11PM  Astellas Up on Pipeline Update, Oncology in Focus (revised) Zacks
02:06PM  Medivation Significantly Undervalued, With Xtandi Weeks Away From Prostate Cancer Label Expansion at Seeking Alpha
16-Jul-14 02:50PM  Astellas Up on Pipeline Update, Oncology in Focus Zacks
14-Jul-14 02:36PM  Earnings Preview: Abbott Laboratories and Johnson & Johnson at Motley Fool
10-Jul-14 04:10PM  Medivation Announces Change in Executive Management Team Marketwired
02:03PM  Medivation Set To Go Higher As Prostate Cancer Drug Xtandi Quickly Approaches Blockbuster Status at Seeking Alpha
07-Jul-14 04:32PM  3 Reasons to Buy Medivation Inc. at Motley Fool
03-Jul-14 01:04PM  3 Stocks Underperforming Today In The Health Care Sector at TheStreet
02-Jul-14 05:58PM  Roche Holding Ltd Is Betting Billions on This New Blockbuster at Motley Fool
10:28AM  Aegis Capital Believes Seragon Deal Underscores Value In Medivation Benzinga
01-Jul-14 04:16PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Se EDGAR Online
25-Jun-14 06:24AM  Medivation Xtandi sales estimates raised at Citigroup at theflyonthewall.com
24-Jun-14 11:34AM  Stratasys, 3D Systems And Medivation Lead Small-Cap Bets For Back Half Of 2014 at Forbes
23-Jun-14 09:33AM  UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer Survey Benzinga
18-Jun-14 08:40AM  Moving Average Crossover Alert: Medivation (MDVN) Zacks
16-Jun-14 04:10PM  Medivation Again Voted Among Top Workplaces in the SF Bay Area Marketwired
11-Jun-14 04:10PM  Medivation Founder, President and Chief Executive Officer David Hung, M.D. Named an EY Entrepreneur Of The Year(TM) 2014 Award Winner in Northern California Marketwired
06-Jun-14 06:04PM  Why Wall Street Hates Dendreon Corp. at Motley Fool
04-Jun-14 07:45AM  Will Medivation (MDVN) Continue to Surge Higher? Zacks
07:08AM  Earnings Estimates Moving Higher for Medivation (MDVN): Time to Buy? Zacks
01-Jun-14 09:01AM  New England Journal of Medicine Publishes Results from Phase 3 PREVAIL Trial of Enzalutamide in Men with Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy PR Newswire
09:01AM  New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial of Enzalutamide in Men With Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy Marketwired
29-May-14 08:20AM  3 More Surges In Biotech Short Interest (AMGN, MDVN, PCYC) Benzinga
07:32AM  The Spectranetics (SPNC) Crumbles: Stock Falls by 8.1% Zacks
22-May-14 07:40AM  Medivation initiated with a Buy at Stifel at theflyonthewall.com
20-May-14 12:38PM  Why I'm Still Avoiding Dendreon at Motley Fool
15-May-14 11:01AM  Options with decreasing implied volatility: GOGO MDVN FOSL NUAN DANG at theflyonthewall.com
14-May-14 05:01PM  Enzalutamide Data, Including Additional Results From the PREVAIL Trial, To be Presented at Upcoming ASCO Annual Meeting PR Newswire
05:01PM  Enzalutamide Data, Including Additional Results From the PREVAIL Trial, to Be Presented at Upcoming ASCO Annual Meeting Marketwired
11:11AM  Medivation Inc Stock Upgraded (MDVN) at TheStreet
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase III PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI. The company is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seely LynnChief Medical OfficerOct 16Option Exercise10.595,00052,92564,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 16Sale93.975,000469,85059,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 15Option Exercise8.0024,346194,73784,200Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 15Sale89.1124,3462,169,36359,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerSep 18Option Exercise10.5925,000264,62584,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 18Sale99.8125,0002,495,15859,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 17Option Exercise8.4630,000253,80089,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 17Sale97.3630,0002,920,72759,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 09Option Exercise10.5920,000211,70079,022Sep 11 06:04 PM
Seely LynnChief Medical OfficerSep 09Sale94.6020,0001,892,01659,022Sep 11 06:04 PM
Seely LynnChief Medical OfficerAug 27Option Exercise10.5914,300151,36673,322Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 27Sale89.6114,3001,281,42359,022Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 26Option Exercise10.595,70060,33564,722Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 26Sale88.955,700507,03259,022Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 13Option Exercise8.3920,000167,82579,022Aug 14 08:00 PM
Seely LynnChief Medical OfficerAug 13Sale83.6220,0001,672,45659,022Aug 14 08:00 PM
Seely LynnChief Medical OfficerAug 12Option Exercise9.3912,500117,31371,522Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 12Sale84.0112,5001,050,12559,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 08Option Exercise9.3913,000122,00572,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 08Sale82.0613,0001,066,82159,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerJul 22Option Exercise6.747,50050,51366,522Jul 23 06:19 PM
Seely LynnChief Medical OfficerJul 22Sale73.967,500554,71059,022Jul 23 06:19 PM
Seely LynnChief Medical OfficerJul 02Option Exercise9.3912,000112,62071,022Jul 07 07:35 PM
Seely LynnChief Medical OfficerJul 02Sale79.0212,000948,19459,022Jul 07 07:35 PM
Seely LynnChief Medical OfficerJun 18Option Exercise6.747,50050,51366,522Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 18Sale75.007,500562,53059,022Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 03Option Exercise6.747,50050,51366,522Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 03Sale74.507,500558,76059,022Jun 19 04:35 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 18Option Exercise10.5940,000423,40070,830Feb 19 04:58 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 18Sale82.7940,0003,311,64630,830Feb 19 04:58 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 11Option Exercise10.5940,000423,40070,830Feb 12 05:34 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 11Sale80.8340,0003,233,12130,830Feb 12 05:34 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 05Option Exercise10.5940,000423,40070,830Feb 06 05:24 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 05Sale73.4640,0002,938,57430,830Feb 06 05:24 PM
Machado Clarence PatrickChief Business Officer and CFOJan 28Option Exercise10.5940,000423,40070,830Jan 29 07:33 PM
Machado Clarence PatrickChief Business Officer and CFOJan 28Sale75.4340,0003,017,12230,830Jan 29 07:33 PM
Hung DavidPresident and CEOJan 27Option Exercise5.88150,000882,0001,100,204Jan 28 05:39 PM
Hung DavidPresident and CEOJan 27Sale73.50150,00011,025,357950,204Jan 28 05:39 PM
Machado Clarence PatrickChief Business Officer and CFOJan 21Option Exercise10.5940,000423,40070,830Jan 23 07:24 PM
Machado Clarence PatrickChief Business Officer and CFOJan 21Sale76.2940,0003,051,62730,830Jan 23 07:24 PM
Rhodes Jennifer JGC & Chief Compliance OfficerJan 21Sale76.2814,0001,067,9496,000Jan 23 07:23 PM